Journal of Chemotherapy最新文献

{"title":"Aminoglycoside antibiotics as first-line treatment of acute appendicitis and cholecystitis.","authors":"Lučka Šetinc, Tadeja Pintar, Aleksandar Zafirovski, Uroš Godnov, Bojana Beović","doi":"10.1080/1120009X.2024.2381158","DOIUrl":"10.1080/1120009X.2024.2381158","url":null,"abstract":"<p><p>We analyzed the efficacy and safety of aminoglycosides in a retrospective study of 415 patients with acute appendicitis and 277 patients with acute cholecystitis. The following variables increased the incidence of postoperative complications, defined as surgical site infection, recurrent intraabdominal infection, non-infectious post-operative complication, or death: age (<i>p</i> = 0.016 and 0.011), kidney disease (<i>p</i> = 0.019 and <0.001), and ASA Score (<i>p</i> < 0.001). The type of antibiotic therapy did not have a statistically significant effect on the incidence of postoperative complications in patients with acute appendicitis and cholecystitis (<i>p</i> = 0.561 and 0.547, respectively). A linear regression model showed a higher complication rate in patients with kidney disease (<i>p</i> = 0.014) and neoplasms (<i>p</i> = 0.013); the type of antibiotic therapy did not have a significant effect on the outcome (<i>p</i> = 0.765). There was no statistically significant difference in the post-treatment levels of creatinine in patients treated with aminoglycosides (gentamicin 3 mg/kg once daily) and in those who received other antibiotics (<i>p</i> = 0.75).</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"307-316"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRIM24/ZFX affects the stemness and resistance to 5-FU of colorectal cancer cells.","authors":"Xuming Yao, Zhiping Yang, Guoxin Hou, Jialu Jiang, Lvbin Wang, Jin Jiang","doi":"10.1080/1120009X.2024.2376422","DOIUrl":"10.1080/1120009X.2024.2376422","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the second leading cause of cancer death, and about 10% of all malignancies are CRC. Cancer stem cells are considered main culprits in CRC treatment resistance and disease recurrence. This study explored the effects of tripartite motif containing 24 (TRIM24) and zinc finger protein, X-linked (ZFX) on CRC cell stemness and 5-FU resistance. A 5-FU-resistant cell line (HT29-5-FU) was constructed for functional analysis of CRC 5-FU-resistant cells. qRT-PCR and western blot (WB) were employed to analyze mRNA and protein levels of ZFX in 5-FU resistant cells and sensitive cells. WB was also utilized to analyze the surface markers of stem cells in each group. CCK-8 assay determined the IC₅₀ values of different cell groups treated with 5-FU. The sphere-forming ability of cells in each group was determined using tumor sphere assay. Dual-luciferase reporter gene assay validated binding of ZFX to TRIM24. ZFX was highly expressed in HT29-5-FU cells. Silencing ZFX significantly reduced the 5-FU resistance and IC₅₀ value of HT29-5-FU cells, and the surface markers and cell sphere-forming ability of stem cells were also significantly reduced. The function of HT29 cells was opposite when ZFX was overexpressed. In CRC cells, TRIM24 was an upstream transcription factor of ZFX, and they interacted with each other. TRIM24 activated the expression of ZFX to influence the stemness and 5-FU resistance of cells. The TRIM24/ZFX regulatory axis affected the stemness of CRC cells and their sensitivity to 5-FU, providing potential drug targets for novel therapeutic avenues for CRC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"353-364"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.","authors":"Özgecan Dülgar, Sema Türker, Gül Başaran, Murat Araz, Ahmet Taner Sümbül, Dilek Çağlayan, Özge Gümüşay, Sedat Biter, Ahmet Konca, Miraç Özen, Hacer Demir, Melek Özdemir, Fatih Karataş, Elif Şahin, Eyyüp Çavdar, Ayşe İrem Yasin, Alper Yaşar, Sümeyra Derin, Metin Pehlivan, Ümmügül Üyetürk, Özlem Özdemir, Erkan Kayıkçıoğlu, Naziye Ak, Teoman Şakalar, Abdullah Sakin, Mahmut Büyükşimşek, Seval Ay, İsmail Ertürk, Sinem Akbaş, Kadriye Bir Yücel, Mahmut Gümüş","doi":"10.1080/1120009X.2024.2366683","DOIUrl":"10.1080/1120009X.2024.2366683","url":null,"abstract":"<p><p>We aimed to evaluate the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab plus trastuzumab and taxane. We reviewed the medical records of patients who were diagnosed with Human Epidermal Growth Factor Receptor 2 (HER-2) positive metastatic breast cancer and received pertuzumab and then TDM-1 between January 2014 and January 2021 from twenty- five cancer centers. The Kaplan- Meier method estimated progression-free survival (PFS) and overall survival (OS). Additionally, objective response rate (ORR), clinical benefit rate (CBR), and safety were evaluated. One hundred fifty-three patients were included,79.1% of the patients received TDM-1 in the second line, 90.8% had visceral metastasis, and 30.7% had central nervous system involvement. The PFS and OS of TDM-1 were evaluated according to the number of previous lines (on the 2nd line or more than two lines) metastatic sites (visceral and non-visceral) and the presence of central nervous metastasis. In TDM-1 therapy, PFS in second line therapy was ten months (95% CI: 7.7 - 12.2); this was statistically higher than later-line PFS, which was six months (95% CI: 3.3 to 8.6) (<i>p</i> = 0.004). The median OS time was 25 months (95% CI: 21.0 to 28.9) in patients treated with TDM-1 in the second line and 19 months (95% CI: 12.3 to 25.6) in patients who received later than the second line(<i>p</i> = 0.175). There were no significant differences in PFS time of patients with and without visceral and central nervous metastases. Our study showed that TDM-1 was also effective in patients using pertuzumab, contributes significantly to PFS when used in the second line compared to its use in the later line, and does not make any difference in OS.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"334-340"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alternatives for the administration of oral antineoplastics in patients with swallowing difficulties.","authors":"E Tejedor Tejada, S Gonzalez Suárez, T Lizondo López, C López-Cabezas, D Soy Muner","doi":"10.1080/1120009X.2024.2354621","DOIUrl":"10.1080/1120009X.2024.2354621","url":null,"abstract":"<p><p>Oncology patients often experience swallowing difficulties, which can compromise adherence to treatment and consequently reduce its effectiveness. Improper handling of these hazardous drugs can lead to the risk of inhalation of particles or other exposures endangering the health of the persons involved such as nurses and pharmacists. The aim of this review is to analyse and update the recommendations for the manipulation of oral antineoplastic drugs in patients with swallowing difficulties. A literature review of articles, websites, guidelines and other documents published up to about the conditions of handling and administration of oral antineoplastic agents in oncology and oncohaematology was carried out. A table of 110 active principles was compiled. The information was grouped according to the name of the drug, instructions for oral and nasogastric tube administration and suggested recommendations. Among the drugs reviewed, 66.4% were suitable for dissolution. Although there is a lot of information in the literature, the nonstop development of new oncological drugs requires continuous updating. Therefore, we have collected the most recent data to provide a consultation tool for healthcare professionals and patients with swallowing difficulties.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"293-306"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 throughout pandemic waves and virus variants: a real-life experience in an Italian hospital.","authors":"Silvia Dettori, Giorgia Brucci, Federica Portunato, Marta Ponzano, Laura Magnasco, Michele Mirabella, Federica Magnè, Emanuele Delfino, Elisa Balletto, Chiara Sepulcri, Antonio Vena, Daniele Roberto Giacobbe, Cristina Marelli, Lorenzo Ball, Malgorzata Mikulska, Antonio Di Biagio, Bianca Bruzzone, Alessio Signori, Sara Mora, Mauro Giacomini, Chiara Dentone, Matteo Bassetti","doi":"10.1080/1120009X.2024.2384321","DOIUrl":"10.1080/1120009X.2024.2384321","url":null,"abstract":"<p><p>New therapies and vaccines changed the management of COVID-19. The aim of this retrospective study was to describe characteristics, in-hospital mortality and its predictors in patients with moderate/severe COVID-19, considering the 4 different pandemic waves and viral variants' prevalence from February 2020 to January 2022. Among 1135 patients included, 873 (77%) had at least one comorbidity, 177 (16%) were immunocompromised. From waves 1 to 4, patients with severe respiratory failure and ICU admission decreased over time (<i>p</i> < 0.001), like the length of in-hospital stay (<i>p</i> < 0.001). Despite a reduction of in-hospital mortality from 19% to 11%, increased risk of death was related to older age and immunocompromising conditions, especially during the 4th wave (HR = 5.07 and HR = 10.86, <i>p</i> < 0.001 respectively) while remdesivir treatment in the 3rd wave (HR = 0.41, <i>p</i> = 0.010) and positive serology (aHR = 0.66, <i>p</i> = 0.027) were protective for survival. These data support the need for tailoring vaccine campaign for future COVID-19 waves.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"317-325"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The crucial relationship between vancomycin minimum inhibitory concentration and therapeutic efficacy against methicillin-resistant coagulase-negative staphylococci.","authors":"Yusuke Niinuma, Keisuke Kagami, Mitsuru Sugawara, Yoh Takekuma","doi":"10.1080/1120009X.2024.2394326","DOIUrl":"10.1080/1120009X.2024.2394326","url":null,"abstract":"<p><p>The area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio was used as an indicator of the clinical efficacy of vancomycin. However, the target AUC/MIC has not been set for methicillin-resistant coagulase-negative staphylococci (MR-CNS), and the effectiveness of vancomycin in strains with high MIC is unknown. Therefore, we aimed to investigate the relationship between the vancomycin MIC and therapeutic efficacy in patients with MR-CNS bacteremia. The primary outcome was the difference in treatment failure rate when the MR-CNS vancomycin MIC was 1 or 2 µg/mL. The treatment failure rate did not significantly differ between the two groups (MIC 1 vs. MIC 2: 27.0% vs. 31.0%; <i>p</i> = 0.779). As a result of multivariate analysis, AUC/MIC_0-24 h ≤230 was extracted as risk factor for treatment failure, suggesting the importance of a sufficient initial loading dose and early blood concentration monitoring to increase AUC/MIC_0-24 h for successful treatment.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"326-333"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway.","authors":"Teng Ren, Hongpei Zhang, Yurou Liu, Juan Wang, Miaomiao Liu, Yanli Chen","doi":"10.1080/1120009X.2025.2522508","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2522508","url":null,"abstract":"<p><p>Chidamide, a histone deacetylase inhibitor with established anti-tumor properties, requires further investigation regarding its specific impact on lung cancer progression. Our results showed that chidamide treatment significantly inhibited proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells while inducing apoptosis. The treatment with chidamide also downregulated methyltransferase 3 (METTL3), the catalytic subunit of the N6-adenosine-methyltransferase complex, in A549 and H1299 cells. Overexpression of METTL3 reversed the inhibitory effects of chidamide on NSCLC cell progression. Furthermore, we found that METTL3 stabilized EPH receptor A7 (EPHA7) expression through an m6A-dependent mechanism. Conversely, overexpression of EPHA7 counteracted the effects of METTL3 silencing or chidamide treatment in both cell lines. <i>In vivo</i>, chidamide treatment reduced EPHA7 protein expression by regulating METTL3, leading to inhibited tumor growth. Collectively, these findings identified the METTL3/EPHA7 axis as a key mediator of chidamide's anti-tumor effects, suggesting chidamide's potential as a novel therapeutic strategy for NSCLC.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.","authors":"Tetsuo Shimizu, Masayuki Nomoto, Yoshiko Nakagawa, Yasuhiro Gon","doi":"10.1080/1120009X.2025.2524914","DOIUrl":"10.1080/1120009X.2025.2524914","url":null,"abstract":"<p><p>Response is a surrogate marker of survival used to determine the efficacy of cancer chemotherapy. However, it is unclear whether the impact of the response on survival depends on the ICI type. This study aimed to assess whether the impact of response on survival differed by the ICI type. We conducted a study on 137 patients who received ICIs (pembrolizumab or atezolizumab) plus chemotherapy for chemotherapy-naïve advanced NSCLC. We analyzed the association between response and survival for each type of ICIs. In the response group, the pembrolizumab-based regimen had significantly more prolonged PFS than the atezolizumab-based regimen (48.1 vs. 8.6 months, P < 0.01). OS was also significantly different between the two groups (Not reached vs. 32.5 months, P = 0.04). Multivariate analysis showed that the pembrolizumab regimen reduced the risk of disease progression by 63% compared to the atezolizumab regimen. The impact of the response on survival differs according to the ICI type.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety analysis of oral <i>isavuconazole</i> therapy of invasive pulmonary aspergillosis.","authors":"Yanli Gu, Rong Zhang, Wei Ding, Bing Sun, Wei Chen, Zili Meng, Liang Chen","doi":"10.1080/1120009X.2025.2523659","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2523659","url":null,"abstract":"<p><p>This retrospective study aimed to explore the efficacy and safety of oral isavuconazole in treating invasive pulmonary aspergillosis (IPA). Among 31 enrolled patients, 21 survived and 10 died by the 42-days follow-up. The mean hospitalization duration was 21.81 ± 8.03 days, with isavuconazole administered for a mean of 25.10 ± 12.87 days. Survivors received isavuconazole for significantly longer period than non-survivors (28.62 vs 17.70 days, <i>P</i> = 0.025). The time to initiation of isavuconazole was significantly shorter in survivors compared to non-survivors (7.86 vs 14.4 days, <i>P</i> = 0.013). Early initiation of treatment was significantly associated with a shorter hospital stay (16.33 vs 25.83 days, <i>P</i> < 0.001). No significant adverse effects were observed in laboratory parameters, and no patients discontinued treatment due to side effects. These findings suggest that early oral administration of isavuconazole may reduce mortality rates and shorten hospitalization duration in patients with IPA. The treatment demonstrated a favourable safety profile, with minimal adverse reactions.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of dostarlimab plus chemotherapy <i>versus</i> pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.","authors":"Tong Liu, Xin Zhang, Bingjie Liu, Yao Yao, Ruihong Yao, Zhiqiang Tong, Xue Teng, Mei Dong, Lu Zhong","doi":"10.1080/1120009X.2025.2524906","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2524906","url":null,"abstract":"<p><p>Lung cancer is one of the most common malignant cancers in most countries, and non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Checkpoint inhibitor immunotherapy is the preferred therapy for metastatic NSCLC patients who do not exhibit EGFR exon 19 deletion or L858R or ALK, RET, or ROS1 rearrangements. A recent clinical study (PERLA, NCT04581824) reports that dostarlimab has comparable effectiveness to pembrolizumab and presents clinical reliability as a first-line treatment for patients with metastatic non-squamous NSCLC. Our study employed a partitioned survival model (PSM) to evaluate the cost-effectiveness of dostarlimab plus chemotherapy compared to pembrolizumab plus chemotherapy as a first-line treatment of metastatic NSCLC from the perspective of healthcare payers in China. We found that when the time horizon was 10 years, dostarlimab plus chemotherapy was not cost-effective at the willingness to pay (WTP) threshold of 287,247 Chinese yuan (CNY)/QALY (35,057 EUR/QALY at an exchange rate of 1 CNY = 0.122 EUR).</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}